healthcare

Bristol Myers Squibb Company (NYSE:BMY) on Friday won U.S. approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis. The decision gives patients another option for joint and skin symptoms tied to the autoimmune disease. The U.S. Food and Drug Administration approved the...

The Department of Government Efficiency (DOGE) open-sourced on Friday what it describes as the largest Medicaid dataset in the department's history, containing aggregated provider-level claims data from January 2018 through December 2024. Dataset Enables Fraud Detection Analysis The dataset...

Roundhill Investments CEO Dave Mazza told Benzinga that President Donald Trump‘s return to the White House has put an emphasis on three key sectors and themes that could benefit investors. Here's a look at why thematic investing matters and which themes are benefiting from Trump. Trump...

Major U.S. benchmarks finished Monday higher, with the Dow Jones Industrial Average climbing 0.6% to 49,412.40, the S&P 500 adding 0.5% to 6,950.23, and the Nasdaq advancing 0.4% to 23,601.35The anticipation surrounding the earnings of the “Magnificent Seven” stocks, including ...

Long before his historic wager against the U.S. housing market, investor Michael Burry was dissecting a different kind of bubble. This one was unfolding in the American healthcare system and was driven by deeply flawed federal incentives, not unlike the system that is still being followed today....

Mark Cuban recently took to X to question the control insurance companies and Pharmacy Benefit Managers (PBMs) have over healthcare. On Friday, Cuban, the owner of the Dallas Mavericks, posted a series of posts on X challenging the power of insurance companies and PBMs. He suggested that these...

The Food and Drug Administration’s top vaccine regulator is pushing new limits on how vaccines win approval. The tougher standards could cloud prospects for vaccine makers and rattle investors in major healthcare and biotech names. Center for Biologics Evaluation and Research Director Vinay...

Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from retail traders. • BRKB shares are consolidating after recent moves. Track the action here....

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday. It is just below resistance around the $58 level. Novo has been in a major downtrend since June 2024. Since then, it has lost about 60% of its value. But there is a chance that a reversal may be taking place. This is why it is our Stock of...

Billionaire entrepreneur Mark Cuban is aiming for America's health insurance industry, warning that high deductibles are leaving millions of people effectively uninsured despite paying monthly premiums. Cuban Says Rising Deductibles Leave Patients Effectively Uninsured In a post on Monday on X,...

Healthcare technology company Clover Health Investments Corp. (NASDAQ:CLOV) is trading lower after reporting second-quarter financial results after market close on Tuesday. CLOV is seeing a decline in price after-hours. Track it now here. What Happened: The company reported second-quarter revenue...

It's been a rough ride for healthcare investors in 2025. While the S&P 500 is cruising along with a 8.4% year-to-date gain, the healthcare sector has actually posted a negative return of 1.3%, making it the worst performer so far. So, what's dragging it down? A cocktail of regulatory stress and...

IGC Pharma Inc (NYSE:IGC) witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday. What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge...

President Donald Trump is receiving lower approval ratings in July as compared to mid-June and is nearing record lows for his net approval rating since taking office in January. What Happened: Trump's signing of the "Big Beautiful Bill," which has received minimal support from voters, is likely the...

RxSight Inc. (NASDAQ:RXST) plummeted by 34.32% in after-hours trading on Tuesday. The drop followed the company’s decision to revise its 2025 revenue forecast. What Happened: The stock of RxSight Inc. experienced a sharp decline in after-hours trading, closing at $8.40, a 34.32% decrease from...